32 results about "CDKN2A" patented technology

The invention discloses an application of mRNA (messenger Ribonucleic Acid) for coding p16 protein in preparation of a medicine for treating pancreatic cancer. The mRNA for coding the p16 protein comprises a nucleic acid sequence as shown in SEQ ID NO.1-3. The invention also provides an application of the mRNA for coding the p16 protein and a universal RAS inhibitor daraxonrasib in the preparation of a medicine for treating pancreatic cancer in combination with the mRNA for coding the p16 protein and the universal RAS inhibitor daraxonrasib. Further, the mRNA encoding the p16 protein can be entrapped in a lipid nanoparticle. Experiments show that the function of CDKN2A is recovered by delivering p16 mRNA, the sensitivity of pancreatic cancer cells to the daraxonrasib can be enhanced, the drug resistance of the daraxonrasib can be reversed, and a remarkable synergistic anti-tumor effect is shown in various pancreatic cancer mouse models. The invention provides a new combined treatment strategy for the treatment of pancreatic cancer, especially pancreatic ductal adenocarcinoma.

The application provides a method for constructing a spontaneous esophageal precancerous lesion or esophageal cancer non-human animal model and application thereof. The non-human animal model of spontaneous esophageal precancerous lesion or esophageal cancer is obtained by deleting the expression of Trp53 and Cdkn2a in the non-human animal. The non-human animal model prepared by the application can be used as an ideal animal model for screening drug candidates, evaluating the therapeutic effect of drugs, evaluating the toxicological effect of drugs and researching the pathogenesis of esophageal precancerous lesion or esophageal cancer.

Aspects herein include methods, kits, and systems for evaluating a subject comprising detecting genetic mutation(s) in the DNA sequence of one or more oral cavity squamous cell carcinoma (OCSCC) biomarker(s) in a biological sample from the subject comprising DNA, wherein the OCSCC biomarker(s) comprise TP53, CDKN2A, FAT1, CASP8, NOTCH1, PIK3CA, and / or HRAS along with detecting or determining an HPV infection.

Providing a CDKN2a companion diagnostic for interferon therapy for bladder cancer. [Solution] A method for treating bladder cancer, comprising the steps of: diagnosing bladder cancer in a human; measuring the CDKN2A expression level in the human; and subsequently injecting an interferon expression-inducing agent into the human. Non-muscle-invasive bladder cancer (NMIBC) represents the most common disease state in patients with newly diagnosed bladder cancer. Those with high-grade (HG) tumors are at significant risk of both recurrence and progression.

The invention relates to the technical field of biomedicine, in particular to a marker for risk assessment of vitreous retinal lymphoma and application of the marker. The marker comprises mutation sites of vitreoretinal lymphoma related genes, and the vitreoretinal lymphoma related genes comprise BTG1, BTG2, DMD, HLA-A, LRP1B, PTPN11, PTPRD, STAT5A, TGFBR2, VHL, ARID1A, ARID1B, ATM, BCL2, BCL6, BCOR, BRAF, CARD11, CD79A, CD79B, CDKN2A, CDKN2B, EP300, ETV6, EZH2, GNA13, IRF4, JAK1, JAK2, JAK3, KMT2D, MYC, MYD88, NOTCH1, NOTCH2, PIK3CA, PIM1, PRDM1, according to the application, the markers are screened out, a corresponding detection object is designed based on the screened markers, and a vitreous retinal lymphoma risk assessment method with high sensitivity and reliability and a corresponding risk assessment product are constructed. According to the method, an accurate risk judgment result can be obtained based on a comprehensive score of VRL related somatic cell gene mutation in a to-be-detected sample.

The invention discloses a probe set for evaluating pancreatic cancer whole-body tumor load and application thereof.The probe set comprises probes used for detecting gene markers, the gene markers comprise KRAS, TP53, CDKN2A, SMAD4, RNF43, TGFBR2, PIK3CA, BRAF, GNAS and CTNNB1, high-frequency and medication-related sites of pancreatic cancer are covered, targeted capture is conducted on plasma ctDNA independently or when the probe set and a personalized probe set are used in an overlapped mode, and the pancreatic cancer whole-body tumor load is evaluated. And the whole-body tumor load of the pancreatic cancer patient is dynamically monitored in real time.

The invention discloses a CDKN2A and ISG15 interaction key site THR95 and an application of the CDKN2A and ISG15 interaction key site THR95. The invention particularly relates to application of the key site in preparation of a product for diagnosing or inhibiting tumor immune escape. The invention provides a new target spot and a new method for diagnosis and treatment of tumor immune escape by researching key sites of interaction of CDKN2A and ISG15, and has important clinical application value.

The present application relates to the technical field of multi-gene detection, and in particular to a set of capture probes for follicular lymphoma multi-gene detection, a kit and a detection analysis method ARID1A, ARID1B, ATM, ATP6V1B2, B2M, BCL10, BCL2, BCL6, BCL7A, BTG1, BTG2, BTK, CARD11, CCND3, CD58, CD70, CD79A, CD79B, CDK4, CDKN2A The capture probe set comprises capture probes for specifically binding to 74 follicular lymphoma related genes, and the capture probe set preferably comprises nucleotides with sequences as shown in SEQ ID NO. 1-937. The probe set of the present application can realize one-time detection of variation in the full exon region of 74 follicular lymphoma related genes in the sample to be detected in the same system, has high specificity, high average sequencing depth and wide coverage area.

The application belongs to the field of biological medicine, and particularly relates to a group of gene mutations and application thereof in diagnosis of pancreaticobiliary duct cancer. Specifically, the application provides a group of gene mutations for detecting pancreaticobiliary duct cancer, wherein the gene mutations include one or more of AKT1, KRAS, APC, NRAS, ARID1A, PIK3CA, AXIN1, PPP2R1A, BAP1, PTEN, BRAF, SMAD4, CDKN2A, TERT, TP53, EGFR, FBXW7, FGFR2, HRAS, IDH1 and IDH2.

Provided is a method for acquiring data on efficacy of a CDK4 / 6 inhibitor in a lung cancer cell, the method including detecting EGFR gene mutation, and CDKN2A / B gene deletion or loss-of-function mutation in a lung cancer cell derived from a lung cancer patient. Presence of EGFR gene mutation, and CDKN2A / B gene deletion or loss-of-function mutation indicates that the CDK4 / 6 inhibitor has efficacy.

The invention relates to the technical field of molecular biology, in particular to a molecular marker combination and a kit for B lymphoma cell detection or enrichment or PVRL prediction, diagnosis or prognosis, and B lymphoma cells are tumor cells of primary vitreoretinal lymphoma. Specifically, the invention provides a molecular marker combination capable of being used for detecting tumor cells of primary vitreous retinal lymphoma, and the molecular marker combination comprises ZBTB7A and CDKN2A.

A product for diagnosing lung cancer, wherein the product comprises a reagent used for detecting a biomarker in a subject sample, and the biomarker includes PCDH18, CDKN2A and / or HOXA9. The reagent used for determining expression level of the biomarker on the subject sample by quantitative PCR, NGS, Northern blot, Southern blot, microarray, SAGE, immunoassay or mass spectrometry. Methods of immunoassay include ELISA, EIA, agglutination test, nephelometry, turbidimetry, Western blot, immunoprecipitation, immunocytochemistry, flow cytometry and Luminex assay. The reagent comprises a primer, probe and an antibody and the product comprises a kit, nucleic acid membrane strip, a preparation and a chip. The lung cancer may be lung squamous cell carcinoma.

Aspects herein include methods, kits, and systems for evaluating a subject comprising detecting genetic mutation(s) in the DNA sequence of one or more oral cavity squamous cell carcinoma (OCSCC) biomarker(s) in a biological sample from the subject comprising DNA, wherein the OCSCC biomarker(s) comprise TP53, CDKN2A, FAT1, CASP8, NOTCH1, PIK3CA, and / or HRAS along with detecting or determining an HPV infection.

Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated amino acid sequence encoded by mutated CDKN2A. The TCRs may recognize mutated CDKN2A peptide presented by an HLA-A molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

An object of the present invention is to provide a human astrocyte cell population that is differentiated from astrocyte progenitor cells derived from human iPS cells, a manufacturing method for the human astrocyte cell population; and an evaluation method for a test substance using the human astrocyte cell population. According to the present invention, there is provided a human astrocyte cell population that is differentiated from astrocyte progenitor cells derived from human iPS cells, the human astrocyte cell population including at least 90% of human astrocytes, in which in the human astrocytes, a) CDKN2A is positive, b) at least one gene marker selected from the group consisting of IGFBP5, NNMT, HLA-DRB1, and HLA-DRB5 is positive, and c) an expression level of C3, which is standardized with GAPDH of a reference gene, is 0.05 copies / copies or less.

The present disclosure provides, inter alia, compositions and methods for treating premature aging of muscle stem cells to combat myopathy by targeting Cdkn2a.

The application relates to the field of biotechnology, in particular to a probe composition for detecting a salivary gland tumor gene panel and application thereof, and further relates to a library construction method, a sequencing method, a kit and a device for the salivary gland tumor gene panel. The probe composition can capture nucleic acid molecules of multiple genes related to salivary gland tumors, such as AKT1, APC, AR, ARID1A, ATM, AXIN1, BAP1, BARD1, BCOR, BRAF, BRCA1, BRCA2, CDH1, CDK11B, CDKN2A, CDKN2B, CREBBP, CTNNB1, CYLD, EGFR and EP300. The nucleic acid molecules in a sample to be analyzed are captured by using the probe composition, and library construction and sequencing are carried out; and the analysis result of the sequencing data is helpful to improving the diagnosis accuracy of salivary gland tumors.

The invention relates to an MTAP and CDKN2A gene fluorescence in-situ hybridization joint detection probe and application thereof, and belongs to the technical field of biological medicine. The invention provides a probe and a probe composition for tumor diagnosis and prognosis evaluation, the probe composition comprises a first probe for detecting an MTAP gene and a second probe for detecting a CDKN2A gene, and the first probe and the second probe are respectively marked with a first fluorescein and a second fluorescein which can generate different colors; the invention provides a fluorescence in situ hybridization combined detection method for simultaneously detecting MTAP and CDKN2A gene variation and a kit thereof. The application range is wide, the kit can be used for various tissue and cell samples needing to detect MTAP and CDKN2A gene states at the same time, and two results are obtained through one-time detection and accord with the targets of quality improvement and efficiency improvement of clinical examination; the method has a very wide application prospect in evaluating the malignant degree of various cancers and selecting a clinical precise treatment strategy.

The invention provides a detection method and device for screening CDKN2A homozygous deletion in central nervous system glioma, equipment and a storage medium. Relates to the technical field of tumor molecular diagnosis and pathology. The method comprises the following steps: acquiring a slice digital image; calculating a first score of the slice digital image; inputting the slice digital image into a pre-trained deep learning model, and performing automatic identification and scoring on an MATP signal in the image to obtain a second score; respectively comparing the first score and the second score with CDKN2A gene homozygous deletion gold standards of corresponding samples, and drawing a first ROC curve and a second ROC curve; and respectively determining a first optimal truncation threshold and a second optimal truncation threshold based on the first ROC curve and the second ROC curve, and taking the first optimal truncation threshold and the second optimal truncation threshold as a judgment basis for screening CDKN2A homozygous deletion. According to the application, the CDKN2A homozygous deletion in the glioma of the central nervous system can be quickly and accurately screened.

The invention provides a construction method and application of a spontaneous esophageal precancerous lesion or esophageal cancer non-human animal model. The spontaneous esophageal precancerous lesion or esophageal cancer non-human animal model is obtained through expression deletion of Trp53 and Cdkn2a of a non-human animal. The non-human animal model prepared by the invention can be used as an ideal animal model for screening drug candidates, evaluating drug treatment effects, evaluating drug toxicological effects and researching esophageal precancerous lesions or pathogenesis of esophageal cancer.

The invention provides a method, a system and equipment for predicting asthma. The method for predicting asthma is carried out based on a computer and specifically comprises the following steps: acquiring data: acquiring expression level data of biomarkers ATP7B, CDKN2A, GLS, LIAS, LIPT1, MTF1, PDHA1 and PDHB in a sample to be detected; data processing: inputting expression level data of the biomarkers into the constructed asthma prediction model to calculate a risk score; predicting the risk of the to-be-detected sample suffering from asthma based on the risk score, and if the risk score is higher than a threshold value, obtaining a classification result that the risk of the to-be-detected sample suffering from asthma is low; if the risk score is lower than a threshold value, obtaining a classification result of high asthma risk of the to-be-detected sample; and outputting a result.

The present invention provides a method with which it is possible to objectively and accurately assess the risk of onset of esophageal cancer, pharyngeal cancer, and / or oral cancer, non-invasively and with little burden on the subject, and an onset prediction model having high accuracy for these cancers. The purpose of the present invention is also to provide a kit that can be used in the assessment method and the onset prediction model.　The present invention is a method for predicting the onset and / or assessing the risk of esophageal cancer, pharyngeal cancer, or oral cancer in a subject, the method being characterized by comprising (A) a step for identifying a mutation in at least one gene selected from the group consisting of CHEK2, TP53, NOTCH 1, CDKN2A, NOTCH2, FAT1, PPM1D, AJUBA, ARID1A, ZFP36L2, ZNF750, and CUL3 in a nucleic acid specimen extracted from a biological sample derived from the oral mucosa of the subject and (B) a step for calculating and scoring the total (Sum of VAFs) allele frequency (VAF) and / or the total mutations (Number of mutations) of the mutation identified in step (A).

The invention discloses a construction method and application of a KPCDK mouse model originated from inflammatory senescence cells induced by inflammation and senescence, the construction method of the model comprises the following steps: hybridizing a mouse expressing a Cdkn2a-CreER2 gene with a mouse in which both KrasLSL-G12D and Trp53R172H are mutated to obtain a KPCDK mouse, and the genotypes of the KPCDK mouse are KrasLSL-G12D / +, Trp53R172H / + and Cdkn2a-CreER2 / +; the KPCDK mouse model is obtained by carrying out injection induction on a KPCDK mouse by using rain frog element and tamoxifen. According to the application, through the combined action of the leifrotin and the tamoxifen, the spontaneous tumorigenesis experiment period can be shortened, the experiment efficiency can be improved, the experiment cost can be saved, and a basis is better provided for the research of an aging tumorigenesis mechanism caused by pancreatic cancer and inflammation and the research and development of medicines.

The invention provides a method for acquiring potency data of a CDK4 / 6 inhibitor in lung cancer cells. The method comprises the step of detecting EGFR gene mutation and CDKN2A / B gene deletion or function loss mutation in lung cancer cells from a lung cancer patient. The presence of EGFR gene mutation and CDKN2A / B gene deletion or loss of function indicates that the CDK4 / 6 inhibitor has efficacy.

To provide biomarkers to predict effective treatment of cancer using an MDM2 antagonist.SOLUTION: Biomarkers are (i) BAP1; and / or (ii) CDKN2A; and / or (iii) one, two, three, four, five, six, seven, eight, nine, ten or more of CXCL10, CXCL11, RSAD2, MX1, BATF2, IFI44L, IFITM1, ISG15, CMPK2, IFI27, CD74, IFIH1, CCRL2, IFI44, HERC6, ISG20, IFIT3, HLA-C, OAS1, IFI35, IRF9, EPSTI1, USP18, BST2, CSF1, C1S, DHX58, TRIM14, OASL, IRF7, LGALS3BP, DDX60, LAP3, LAMP3, PARP12, PARP9, SP110, PLSCR1, WARS, STAT1, IRF3, IRF5, and the like.SELECTED DRAWING: None

The application discloses a probe set for evaluating systemic tumor burden of pancreatic cancer and application thereof, wherein the probe set comprises probes for detecting gene markers, the gene markers comprising KRAS, TP53, CDKN2A, SMAD4, RNF43, TGFBR2, PIK3CA, BRAF, GNAS and CTNNB1, covering high-frequency and drug-related sites of pancreatic cancer, and the systemic tumor burden of a pancreatic cancer patient is monitored in real time and dynamically by performing targeted capture on plasma ctDNA alone or in combination with a personalized probe set.

The application discloses a quantitative digital PCR detection reagent for detecting promoter methylation of pan-solid tumor multi-genes and application, which comprises methylation-specific primer probe pairs and unmethylation-specific primer probe pairs for detecting CDKN2A, RASSF1A, RARbeta2 and SHOX2 genes. The application adopts the digital PCR technology to detect pan-solid tumor multi-genes (CDKN2A, RASSF1A, RARbeta2 and SHOX2), has greater tumor discrimination, and has important significance for tumor screening and risk assessment, early diagnosis, staging and typing, prognosis judgment and treatment detection. The method has higher sensitivity, higher accuracy and absolute quantification, is not affected by amplification efficiency, can more efficiently detect extremely low abundance (0.1%) promoter methylation, and is suitable for screening of a large number of clinical samples.

The invention discloses a CDKN2A and ISG15 interaction key site MET53 and an application of the CDKN2A and ISG15 interaction key site MET53. In particular to application of a CDKN2A protein MET53 site in preparation of products for diagnosing or inhibiting tumor immune escape, tumor epithelial-mesenchymal transition, tumor cell matrix metalloproteinase expression quantity and tumor cell PD-L1 level and a method for preparing cancer cells with inhibited invasion and metastasis capacity, and provides a new way for precise diagnosis and treatment of tumors. The important clinical application value is realized.

The invention relates to the field of tumor diagnosis and treatment, and provides application of CDKN2A and ISG15 proteins in diagnosis or treatment of brain metastasis of lung cancer. The invention particularly relates to application in preparation of products for diagnosing or inhibiting lung cancer brain metastasis, tumor immune escape, tumor epithelial-mesenchymal transition, tumor cell invasion and migration ability, tumor cell matrix metalloproteinase expression quantity and tumor cell PD-L1 level. The invention provides a more effective way for diagnosis or treatment of brain metastasis of lung cancer, and has important clinical application value.

The invention relates to a CD274 and CDKN2A gene fluorescence in-situ hybridization joint detection probe and application thereof, and belongs to the technical field of biological medicine. The invention provides a probe and a probe composition for tumor diagnosis and prognosis evaluation, the probe composition comprises a first probe for detecting a CD274 gene and a second probe for detecting a CDKN2A gene, and the first probe and the second probe are respectively marked with a first fluorescein and a second fluorescein which can generate different colors; the invention provides a fluorescence in situ hybridization combined detection method for simultaneously detecting CD274 and CDKN2A gene variation and a kit thereof. The method is simple in operation, wide in application range and capable of being used for various tissue and cell samples needing to detect CD274 and CDKN2A gene states at the same time, multiple results are obtained through one-time detection, and the target of quality improvement and efficiency improvement of clinical examination is met; the method has a very wide application prospect in evaluation of prognosis of various cancers.